单绒毛膜双羊膜囊双胎妊娠合并II型选择性胎儿生长受限的管理:成本-效果分析
本研究采用决策分析模型,对10000例单绒毛膜双羊膜囊双胎妊娠合并II型选择性胎儿生长受限的假设队列,比较期待管理、双极脐带凝固、射频消融和胎儿镜激光光凝四种策略的成本-效果。基础分析中射频消融最具成本-效果,增量成本-效果比为每质量调整生命年14243美元;但概率敏感性分析显示双极脐带凝固和期待管理也可能获益,作者认为在缺乏大型临床试验时不应据此指导临床管理。
要点
- 基础分析中射频消融最具成本-效果,增量成本-效果比为每质量调整生命年14243美元。
- 概率敏感性分析中射频消融在78%的运行中具成本-效果,双极脐带凝固20%,期待管理2%,胎儿镜激光光凝0%。
- 作者认为上述发现经敏感性分析并不稳健,在缺乏大型临床试验时不应据此指导管理。
核心结论
- 基础分析中,射频消融是管理单绒毛膜双羊膜囊双胎妊娠合并II型选择性胎儿生长受限最具成本-效果的策略。
- 然而这些发现在敏感性分析中并不稳健,提示双极脐带凝固和期待管理可能获益。
- 在缺乏大型临床试验的情况下,这些数据不应被用来指导管理。
研究设计与样本
- 采用决策分析模型,比较期待管理、双极脐带凝固、射频消融和胎儿镜激光光凝四种策略。
- 假设队列为10000例单绒毛膜双羊膜囊双胎妊娠合并II型选择性胎儿生长受限。
- 概率和效用值来自文献,成本来自医疗成本与利用项目并调整为2023年美元。
- 分析视角为孕妇,时间跨度覆盖子代终生;支付意愿阈值为每质量调整生命年50000美元。
- 进行了单因素和概率敏感性分析。
主要发现
- 基础分析中,射频消融与所有其他干预相比最具成本-效果,增量成本-效果比为每质量调整生命年14243美元。
- 单因素敏感性分析显示,胎儿死亡和严重神经发育损害的效用值以及32周前早产的成本对模型结果影响最大。
- 概率敏感性分析中,射频消融在78%的运行中具成本-效果,双极脐带凝固20%,期待管理2%,胎儿镜激光光凝0%。
- 与期待管理相比,射频消融减少58例28周前分娩、减少273例严重神经发育损害、增加22例32周后分娩。
- 与胎儿镜激光光凝相比,射频消融减少259例严重神经发育损害、增加3177例32周后分娩。
关键数值与推荐
- 增量成本-效果比阈值为每质量调整生命年50000美元,用于定义支付意愿。
- 射频消融的增量成本-效果比为每质量调整生命年14243美元。
- 概率敏感性分析中射频消融具成本-效果的比例为78%,双极脐带凝固为20%,期待管理为2%,胎儿镜激光光凝为0%。
临床怎么用
- 作者认为在缺乏大型临床试验的情况下,这些数据不应被用来指导管理。
- 作者建议未来研究应在前瞻性多中心队列中评估II型选择性胎儿生长受限的管理策略与长期新生儿结局(包括生活质量指标)的关系。
局限性
- 作者指出这些发现在敏感性分析中并不稳健,提示双极脐带凝固和期待管理可能获益。
- 作者指出在缺乏大型临床试验的情况下,这些数据不应被用来指导管理。
- 作者建议未来研究应在前瞻性多中心队列中评估与长期新生儿结局(包括生活质量指标)相关的管理策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Monochorionic twin gestations affected by Type-II selective fetal growth restriction (sFGR) are at increased risk of intrauterine fetal demise, extreme preterm birth, severe neurodevelopmental impairment (NDI) and neonatal death of one or both twins. In the absence of a consensus on the optimal management strategy, we chose to evaluate which strategy was cost-effective in the setting of Type-II sFGR. METHODS: A decision-analytic model was used to compare expectant management (EM), bipolar cord occlusion (BCO), radiofrequency ablation (RFA) and fetoscopic laser photocoagulation (FLP) for a hypothetical cohort of 10 000 people with a monochorionic diamniotic twin pregnancy affected by Type-II sFGR. Probabilities and utilities were derived from the literature. Costs were derived from the Healthcare Cost and Utilization Project and adjusted to 2023 USD. The analytic horizon, taken from the perspective of the pregnant patient, extended throughout the life of the child or children. An incremental cost-effectiveness ratio of 50 000 USD per quality-adjusted life year defined the willingness-to-pay threshold. One-way and probabilistic sensitivity analysis was also performed. RESULTS: For base-case estimates, RFA was the most cost-effective strategy compared with all of the other interventions included, with an incremental cost-effectiveness ratio of 14 243 USD per quality-adjusted life year. One-way sensitivity analysis demonstrated that the utilities assigned to fetal demise and severe NDI, as well as the costs of preterm birth before 32 weeks, most strongly impacted the model outcomes. On probabilistic sensitivity analysis, RFA was the most cost-effective strategy in 78% of runs, followed by BCO at 20%, EM at 2% and FLP in 0% of runs. When compared with EM, RFA led to 58 fewer births before 28 weeks' gestation, 273 fewer cases of severe NDI and 22 more deliveries after 32 weeks. When compared with FLP, RFA resulted in 259 fewer cases of severe NDI and 3177 more births after 32 weeks. When compared with BCO, RFA resulted in 1786 more neurologically intact neonates and 34 fewer cases of severe NDI. CONCLUSIONS: On base-case analysis, RFA was found to be the most cost-effective strategy in the management of monochorionic diamniotic twin pregnancies affected by Type-II sFGR. However, these findings were not robust on sensitivity analysis, indicating the potential benefit of BCO and EM. In the absence of large clinical trials, these data should not be taken to guide management. Future studies should evaluate management strategies for Type-II sFGR related to long-term neonatal outcomes, inclusive of quality-of-life indicators, in a prospective multicenter cohort. © 2024 The Author(s). Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology.
引用
- Morgan JC, Rios J, Kahl T, et al. Management of monochorionic diamniotic twin gestation affected by Type-II selective fetal growth restriction: cost-effectiveness analysis. Ultrasound Obstet Gynecol. 2024. PMID: 39602652. doi:10.1002/uog.29135
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。